If you or someone you care for takes a GLP-1 receptor agonist medication such as Ozempic, Wegovy, Mounjaro, or Trulicity, the FDA wants you to know that you may need to stop taking it before your next colonoscopy. In November 2024, the FDA updated the labels on all GLP-1 receptor agonist drugs with a new warning about pulmonary aspiration, a dangerous condition where stomach contents are inhaled into the lungs during sedation. The issue is straightforward: these medications slow down how quickly your stomach empties, which means even if you follow the standard fasting instructions before a procedure, food or liquid may still be sitting in your stomach when you go under. This matters enormously for the millions of older adults who take these drugs and are also due for routine colonoscopies. Consider a 68-year-old woman on weekly Ozempic for type 2 diabetes who shows up for her scheduled colonoscopy having fasted since the night before, just as instructed.
Despite doing everything right, she could still have undigested food in her stomach because Ozempic delayed her gastric emptying. Under sedation, that residual content could come back up and enter her lungs. The FDA describes these events as rare, but the consequences can be severe or even fatal. Beyond the aspiration risk, GLP-1 drugs can also cause constipation and slowed gut motility that interfere with bowel preparation itself, potentially resulting in an incomplete prep that forces patients to repeat the entire colonoscopy process. This article breaks down exactly which drugs are affected, what the major medical societies recommend, how the guidelines differ depending on whether you take a daily or weekly formulation, and what patients with cognitive decline or dementia should discuss with their care teams before any procedure requiring sedation.
Table of Contents
- What Is the New FDA Advisory on GLP-1 Drugs Before Colonoscopy?
- How Long Should You Stop GLP-1 Medications Before a Colonoscopy?
- Why Dementia Caregivers Should Pay Special Attention to This Advisory
- Bowel Prep Complications and What to Do When GLP-1 Drugs Slow Everything Down
- Patients in the Dose Escalation Phase Face the Highest Risk
- How to Talk to Your Doctor About GLP-1 Drugs and Upcoming Procedures
- Where the Science Is Heading and What to Watch For
- Conclusion
- Frequently Asked Questions
What Is the New FDA Advisory on GLP-1 Drugs Before Colonoscopy?
In November 2024, the FDA added a new subsection under “Warnings and Precautions” to the labels of every GLP-1 receptor agonist on the market. The agency cited rare postmarketing reports of pulmonary aspiration in patients who underwent elective surgeries or procedures requiring general anesthesia or deep sedation. These patients had residual gastric contents despite reporting that they followed standard preoperative fasting guidelines. The affected medications include semaglutide (sold as Ozempic, Rybelsus, and Wegovy), liraglutide (Saxenda and Victoza), tirzepatide (Mounjaro and Zepbound), dulaglutide (Trulicity), and exenatide (Byetta and Bydureon BCise). The core pharmacological issue is that GLP-1 receptor agonists work partly by slowing gastric emptying. That mechanism helps control blood sugar and reduces appetite, which is why these drugs are effective for diabetes management and weight loss.
But that same slowed emptying becomes a liability when a patient needs sedation. During a colonoscopy, patients typically receive moderate to deep sedation. If the stomach still contains food or liquid, the risk of regurgitation increases, and aspirated stomach contents can cause a serious lung infection or respiratory failure. To put this in perspective, an estimated 6 million or more Americans currently take GLP-1 medications, and roughly 19 million colonoscopies are performed in the United States each year. The overlap between these two populations is substantial and growing, particularly among adults over 50 who may be managing both metabolic conditions and routine cancer screening schedules. The FDA’s label update does not tell patients to avoid colonoscopies altogether. It tells patients and their doctors to plan more carefully.
How Long Should You Stop GLP-1 Medications Before a Colonoscopy?
The answer depends on which drug you take and which medical society’s guidance your doctor follows, because the recommendations are not uniform. The American Society for Gastrointestinal Endoscopy recommends holding GLP-1 medications for at least 24 hours before the procedure if you take a daily formulation such as Rybelsus or Victoza, and at least 7 days before if you take a weekly injection like Ozempic, Wegovy, or Mounjaro. that seven-day window is significant. If your colonoscopy is on a Thursday, you would need to skip your injection the previous Thursday or earlier. The American Society of Anesthesiologists, which first issued guidance on this topic back in June 2023, updated its position in October 2024 as part of a multi-society collaboration.
Their updated guidance takes a somewhat less restrictive approach: most patients can continue their GLP-1 medications, but those considered high risk, particularly patients experiencing significant gastrointestinal symptoms, should follow a liquid diet for 24 hours before the procedure. Meanwhile, the American Gastroenterological Association has explicitly stated that it does not endorse a blanket recommendation to stop GLP-1 drugs for all patients before endoscopy, favoring individualized risk assessment instead. However, if you or a loved one is experiencing notable GI side effects from these medications, such as persistent nausea, vomiting, bloating, or constipation, the calculus changes. These symptoms suggest that gastric emptying is already significantly delayed, and the risk of residual stomach contents is higher. In these cases, most physicians will lean toward the more conservative approach of stopping the medication well in advance. The lack of consensus among professional societies means that patients need to have a direct conversation with both their prescribing doctor and their gastroenterologist, ideally well before the procedure date, not the week of.
Why Dementia Caregivers Should Pay Special Attention to This Advisory
For families managing dementia, this FDA advisory carries particular weight because it sits at the intersection of several compounding risks. Many older adults with cognitive decline also have type 2 diabetes, a condition increasingly managed with GLP-1 drugs. A person with moderate dementia may not be able to reliably report symptoms like nausea or bloating that would flag them as higher risk for aspiration. They may not remember or understand fasting instructions. And they may not be able to advocate for themselves during the pre-procedure process when a nurse asks whether they have eaten or taken their medications. Consider a scenario where a 74-year-old man with early Alzheimer’s disease has been taking weekly Mounjaro injections managed by his daughter. His primary care doctor orders a routine colonoscopy for colon cancer screening.
If his daughter is not aware of the GLP-1 advisory, she might administer his weekly injection on its normal schedule, not realizing it should have been held a full week before the procedure. On the day of the colonoscopy, the anesthesiologist might not even know the patient is on Mounjaro if the medication list was not updated or communicated clearly. These are not hypothetical gaps. They are exactly the kind of coordination failures that happen routinely in fragmented care. Caregivers who manage medications for someone with cognitive impairment should flag GLP-1 drug use proactively with the gastroenterologist’s office at the time the colonoscopy is scheduled, not at the pre-procedure appointment. Ask specifically whether the medication should be held and for how long. Write the stop date on a calendar. And on the day of the procedure, bring a complete, current medication list and confirm verbally with the nursing staff that the patient is on a GLP-1 drug.
Bowel Prep Complications and What to Do When GLP-1 Drugs Slow Everything Down
The aspiration risk during sedation gets the headlines, but there is a second, more common problem: GLP-1 medications can undermine the bowel preparation itself. Colonoscopy requires the colon to be thoroughly cleaned out, which is why patients drink large volumes of laxative solution the day before. GLP-1 drugs cause constipation and slow gut motility in a significant number of users, and that can mean the prep simply does not work well enough. A gastroenterologist who looks through the scope and sees residual stool may have to abort the procedure, sending the patient home to repeat the entire unpleasant prep process and come back another day. The tradeoff here is real. Stopping a weekly GLP-1 injection a full seven days before the colonoscopy means the patient may experience a temporary loss of blood sugar control or an uptick in appetite, depending on the condition being treated.
For someone with diabetes, that gap requires a management plan, potentially a temporary adjustment in other diabetes medications to bridge the week. For someone using the drug primarily for weight management, a one-week pause is unlikely to have meaningful clinical consequences, but the patient should know that in advance so they do not skip the colonoscopy out of reluctance to stop their medication. Some gastroenterologists are now recommending an extended or split-dose bowel prep for patients on GLP-1 drugs, adding an extra day of clear liquids or using a higher-volume prep solution to compensate for slowed motility. This is an area where the prep instructions you receive in the mail may not account for your specific medication regimen. If you are a caregiver coordinating this for someone else, call the office and ask whether the standard prep protocol needs to be modified. Do not assume the scheduling staff knows what medications the patient takes.
Patients in the Dose Escalation Phase Face the Highest Risk
Not all GLP-1 users carry the same level of risk, and this nuance matters. Patients who are newly starting a GLP-1 medication or who are in the dose escalation phase, the period when the dose is being gradually increased to the target level, are at the highest risk for significant delayed gastric emptying. This is when GI side effects tend to be most pronounced: the nausea, the bloating, the constipation. The body has not yet adapted to the drug’s effects on the gut. If a colonoscopy happens to fall during this early treatment window, the risk of both aspiration and incomplete bowel prep is at its peak.
A patient who has been on a stable dose of Ozempic for a year and tolerates it well is in a different risk category than someone who just started their second month and is still experiencing daily nausea. The problem is that scheduling systems do not cross-reference medication start dates with procedure dates. That coordination falls to the patient or the caregiver. There is also a limitation worth naming directly: the FDA’s warning is based on rare postmarketing reports, not large prospective studies. We do not yet have precise data on exactly how much GLP-1 drugs increase aspiration risk during colonoscopy sedation, or whether the risk differs meaningfully between moderate sedation and deep sedation. What we do know is that the mechanism of action makes the risk biologically plausible and that the consequences of aspiration are serious enough that precaution is warranted even without exact numbers.
How to Talk to Your Doctor About GLP-1 Drugs and Upcoming Procedures
The most practical thing a patient or caregiver can do is raise the subject early. When scheduling any procedure that involves sedation, whether a colonoscopy, an endoscopy, or an elective surgery, tell the scheduling coordinator that the patient takes a GLP-1 medication and name the specific drug. Ask to have that information noted in the pre-procedure chart and request a callback from a nurse or the physician with specific instructions about when to hold the medication.
For example, if a patient takes weekly Mounjaro injections every Monday and has a colonoscopy scheduled for the following Wednesday, the ASGE guidance would suggest skipping the Monday injection one full week before the procedure, not just the Monday immediately before. That means the last injection would be 16 days before the colonoscopy. Getting this timing wrong by even a few days could put the patient at unnecessary risk, so clarifying the plan in writing, not just verbally, is worth the extra effort.
Where the Science Is Heading and What to Watch For
Research into GLP-1 drugs and procedural safety is moving quickly, in part because the sheer number of people taking these medications has made the question urgent. Several academic medical centers are studying whether point-of-care gastric ultrasound, a bedside imaging technique that can show whether the stomach is empty, should become standard before sedation in GLP-1 users. If adopted widely, this could replace the current approach of fixed hold times with a real-time assessment of individual risk.
The broader trend is toward individualized rather than blanket recommendations. The AGA’s refusal to endorse a universal stop rule reflects a recognition that a stable, long-term GLP-1 user with no GI symptoms is fundamentally different from a newly titrating patient with daily nausea. As more data accumulates and professional societies refine their guidelines, patients and caregivers should expect the advice to become more nuanced and more tailored. In the meantime, the safest course is to have the conversation with every doctor involved in the patient’s care and to err on the side of holding the medication when there is any doubt.
Conclusion
The FDA’s November 2024 label update on GLP-1 receptor agonists is not cause for panic, but it is a clear signal that patients and caregivers need to plan ahead before any procedure requiring sedation. The drugs that millions of Americans rely on for diabetes and weight management, including Ozempic, Mounjaro, Wegovy, and Trulicity, slow gastric emptying in a way that can leave food in the stomach even after proper fasting. That residual content creates a real, if rare, risk of pulmonary aspiration during colonoscopy sedation, and it can also sabotage bowel prep. For dementia caregivers, the stakes are compounded by the communication and coordination challenges inherent in managing someone else’s medical care.
The single most important step is to flag GLP-1 drug use early, at the time a procedure is scheduled, and to get written instructions about when to hold the medication. Do not rely on the system to connect these dots automatically. Talk to the prescribing physician, the gastroenterologist, and the anesthesia team. Make sure everyone knows what the patient is taking, how long it has been held, and whether any GI symptoms suggest higher risk. Preparation and communication are the best protection available right now.
Frequently Asked Questions
Can I just skip one dose of my weekly GLP-1 injection before a colonoscopy?
Skipping a single dose may not be sufficient. The ASGE recommends holding weekly GLP-1 injections for at least 7 days before the procedure. Depending on your injection schedule and procedure date, this may mean skipping one or even two doses. Confirm the exact timing with your gastroenterologist.
Does this advisory apply to colonoscopies done with light sedation or no sedation?
The FDA’s warning specifically addresses procedures requiring general anesthesia or deep sedation. If a colonoscopy is performed with minimal sedation or no sedation at all, the aspiration risk from residual gastric contents is lower. However, slowed bowel motility can still affect prep quality regardless of sedation level.
Will stopping my GLP-1 medication for a week cause my blood sugar to spike dangerously?
A temporary pause can affect blood sugar control in patients with type 2 diabetes. Talk to the prescribing doctor about whether a bridging strategy with other diabetes medications is needed during the hold period. For patients using GLP-1 drugs primarily for weight loss, a one-week pause is unlikely to cause significant metabolic consequences.
What if my family member with dementia cannot tell the doctor about their GI symptoms?
This is a critical concern. Caregivers should proactively observe and document any signs of nausea, vomiting, bloating, or constipation in the weeks leading up to the procedure and report these to both the gastroenterologist and anesthesiologist. Patients with significant GI symptoms are considered higher risk under the updated guidelines.
Should I switch to a different diabetes medication permanently to avoid this issue?
Not necessarily. The procedural risk is manageable with proper planning. Switching medications has its own tradeoffs, including potentially worse blood sugar control or different side effects. This is a conversation to have with your endocrinologist based on your full medical picture, not a decision to make based on the colonoscopy alone.
Are there any tests that can show if my stomach is empty before the procedure?
Point-of-care gastric ultrasound can assess stomach contents at the bedside and is being studied as a potential screening tool for GLP-1 users before sedation. It is not yet standard practice everywhere, but you can ask your anesthesiologist whether it is available at your facility.
